Genenta Science careers Europe represent some of the most specialised opportunities available in the European gene therapy and immuno-oncology sector, attracting scientists, clinical professionals, and operational experts to a Nasdaq-listed Italian biotech at the forefront of cancer treatment research. Genenta Science SpA, headquartered in Milan, has developed Temferon, its lead immuno-gene therapy candidate, through a clinical-stage pipeline targeting solid tumors including Glioblastoma multiforme. This guide covers everything international professionals need to understand about working at Genenta Science, including its scientific platform, key personnel, open roles, application expectations, salary context, visa considerations, and how to position yourself for a career in the European gene therapy sector. Whether you are a researcher, clinical operations specialist, bioinformatician, or regulatory professional, this page will help you evaluate Genenta as an employer and navigate your next career step in European biotechnology.

What Is Genenta Science and Why Does It Matter for Biotech Careers in Europe?

Genenta Science SpA is a clinical-stage biotechnology company headquartered in Milan, Italy, focused on developing immuno-gene therapy treatments for solid tumors and blood cancer. The company is listed on the Nasdaq under a Sponsored ADR structure and operates as one of Italy's most internationally visible biotech companies. Genenta Science is founded on pioneering research from Professor Luigi Naldini, a globally recognised figure in the gene therapy field, and the San Raffaele Telethon Institute for Gene Therapy in Milan.

The company's lead programme, Temferon, is an immuno-gene therapy that uses hematopoietic stem progenitor cells engineered with Lenti Viral Vectors to deliver Interferon-alpha directly to the tumor micro-environment via tumor-infiltrating monocytes. This approach is designed to overcome the immune tolerance that solid tumors typically exploit. Genenta has advanced Temferon through European Phase I/II clinical trials, initially targeting Glioblastoma multiforme, the most aggressive form of brain cancer.

For international professionals interested in the European gene therapy sector, Genenta Science represents a rare opportunity to work at the intersection of clinical development, advanced viral vector manufacturing, and translational oncology research. The company collaborates with partners including AGC Biologics for GMP grade viral vector services and LVV Plasmid DNA technology development. Its pipeline includes programmes relevant to both liquid tumors and solid tumors, and it continues to explore Cell and Gene Therapy applications beyond its primary Glioblastoma multiforme indication.

Quick answer: Genenta Science SpA is a Nasdaq-listed Italian biotech company headquartered in Milan that develops immuno-gene therapy treatments using engineered bone marrow stem cells and Lenti Viral Vectors. Its lead programme Temferon targets solid tumors and is in Phase 1/2 clinical trial, making Genenta Science one of the most active clinical-stage biotechnology employers in the European gene therapy sector.

Genenta Science also maintains U.S. operations through a Delaware subsidiary, which means that some roles bridge Italian clinical development teams with American regulatory, investor relations, and commercial functions. The company's position on Nasdaq and its engagement with biotech stocks analysts through platforms such as TipRanks and investor communities reflects its dual presence in European drug development and U.S. capital markets.

For candidates exploring European biotech careers, Genenta Science stands out because of its deep research roots, its university partnership with institutions linked to Professor Luigi Naldini, and its active clinical validation work in a field where most competitors are still in preclinical stages.

KEY TAKEAWAY: Genenta Science is a Milan-based, Nasdaq-listed clinical-stage biotechnology company building immuno-gene therapy treatments for cancer, and it represents one of the most scientifically advanced employer opportunities in the Italian biotech and broader European gene therapy sector.

Understanding the science behind Genenta helps candidates target the right roles and articulate their fit with confidence during application and interview stages.

Genenta Science Leadership, Key Personnel, and Organisational Structure

Understanding the leadership team at Genenta Science is essential for candidates who want to research the company before applying. Genenta Science is led by Pierluigi Paracchi, who serves as Chief Executive Officer and has been a central figure in building the company's commercial and clinical direction since its founding. Paracchi has positioned Genenta Science within both the Italian biotech ecosystem and the international Nasdaq investor community.

Scientific direction is informed by the work of Professor Luigi Naldini, whose foundational research on Lenti Viral Vectors and hematopoietic stem progenitor cell engineering forms the basis of Temferon and the broader Genenta Science pipeline. Professor Naldini's involvement with the San Raffaele Telethon Institute provides the company with a direct link to one of Europe's most respected gene therapy research programmes and signals the academic rigour underpinning Genenta's clinical development approach.

On the operational side, roles such as Clinical Operations Lead and Sr IT Business Partner reflect the company's need to build out cross-functional capabilities as it advances through Phase 1/2 clinical trial stages. Tiziana Pollio has been identified in company communications as a key contact for media and external relations, reachable via Email: tiziana.pollio@genenta.com. Marco Ferrari has also been referenced in Genenta Science Media contexts, contributing to the company's investor and communications activities.

DID YOU KNOW: Genenta Science SpA was co-founded on research principles developed at the San Raffaele Telethon Institute for Gene Therapy, where Professor Luigi Naldini led pioneering work on viral vectors and stem cell engineering that is now the basis for multiple European phase I/II trials.

The Delaware subsidiary structure reflects Genenta's strategy to maintain both a European operational base in Milan and a U.S.-facing corporate identity for investor relations, capital markets engagement, and potential future commercial expansion. This dual structure creates opportunities for candidates with experience in cross-border biotech operations, regulatory affairs, and international clinical development management.

From a hiring culture perspective, Genenta Science has publicly committed to inclusion, accommodations for individuals with disabilities status, and equal opportunity employment principles aligned with both EU employment law and U.S. federal and local laws applicable to its American operations. The company has also addressed pay transparency and compensation information requirements as part of its U.S. operations compliance, particularly relevant for candidates considering roles that interface with its Delaware subsidiary.

Candidates targeting Genenta should be aware that the company values scientific depth, regulatory awareness, and a collaborative culture consistent with an early-to-mid stage clinical biotech. Protected veteran status and disability accommodations are formally recognised in hiring communications, reflecting the company's stated commitment to diversity and non-discrimination principles.

KEY TAKEAWAY: Genenta Science is led by Pierluigi Paracchi with scientific leadership rooted in Professor Luigi Naldini's gene therapy research, and the company maintains both Italian and U.S. operational structures, creating opportunities for candidates with international biotech experience and cross-functional expertise.

Knowing who leads each function at Genenta Science helps candidates align their application to the team most relevant to their background and career goals.

Genenta Science's Scientific Platform: Gene Therapy, Viral Vectors, and Immuno-Oncology

The scientific platform at Genenta Science is built around a highly specialised combination of hematopoietic stem progenitor cell engineering, Lenti Viral Vectors, and Interferon-alpha delivery into the tumor micro-environment. This approach distinguishes Genenta from companies pursuing CAR T-cell immunotherapies or conventional CAR-T cell therapies because it targets the immunosuppressive environment of solid tumors rather than relying on T-cell activation alone.

Temferon is the company's lead advanced therapy programme. It involves harvesting bone marrow stem cells from the patient, engineering those cells using LVV Plasmid DNA technology to express Interferon-alpha conditionally, and then reinfusing the modified cells. Once reinfused, tumor-infiltrating monocytes derived from these engineered stem cells carry the therapeutic payload directly into the tumor micro-environment, where they deliver Interferon-alpha locally. This mechanism is designed to activate immune responses within solid tumors while minimising systemic toxicity.

Quick answer: Temferon is Genenta Science's lead immuno-gene therapy programme, using engineered hematopoietic stem progenitor cells and Lenti Viral Vectors to deliver Interferon-alpha into solid tumors through tumor-infiltrating monocytes. The approach is designed to break immune tolerance in the tumor micro-environment and has progressed to Phase 1/2 clinical trials targeting Glioblastoma multiforme.

GMP manufacturing is a central operational challenge for Genenta Science. Producing GMP grade Lenti Viral Vectors at the scale needed for clinical trials requires significant infrastructure and partnerships. Genenta collaborates with AGC Biologics for viral vector services, leveraging AGC's GMP manufacturing capabilities to support clinical supply. This partnership model is common in the European gene therapy sector, where most early-stage companies rely on contract development and manufacturing organisations for vector production rather than building fully in-house GMP facilities from the outset.

The company is also engaged in research relevant to Stem Cell Therapy, liquid tumors, and exploring how its viral vector platform could be extended into additional cancer treatments. The link between Genenta's gene-therapy approach and emerging areas such as Synthetic biology and 3D bioprinting is indirect but worth noting for candidates interested in the broader trajectory of advanced manufacturing in biotech.

ANEMOCYTE is referenced in Genenta's research ecosystem as a related entity, and the company's pipeline includes exploratory programmes beyond Glioblastoma multiforme. The potential application of the Temferon platform to blood cancer and other tumor types is an active area of scientific discussion within the company and the broader field of Cell and Gene Therapy.

KEY TAKEAWAY: Genenta Science's scientific platform is centred on immuno-gene therapy using engineered stem cells and Lenti Viral Vectors, and candidates with expertise in viral vector manufacturing, GMP operations, hematopoietic biology, or clinical-stage oncology are strongly positioned for roles within this pipeline.

The company's scientific depth creates a high bar for technical roles, which means that preparation and clarity about your specific research or clinical expertise will be critical when applying.

Open Roles and Career Opportunities at Genenta Science in Europe

Genenta Science typically recruits across scientific, clinical, operational, and corporate functions as it progresses through clinical development stages. The most active hiring areas reflect the company's current phase of development: advancing Temferon through Phase 1/2 clinical trial, building out clinical infrastructure, and managing its dual Italian and U.S. operational footprint.

Roles that have been advertised or are commonly needed at a company at Genenta's stage include Clinical Operations Lead, regulatory affairs professionals, biostatisticians, translational scientists, bioinformaticians, GMP manufacturing specialists, quality assurance managers, and Sr IT Business Partner positions supporting digital infrastructure and data systems. Corporate functions including finance, investor relations, and legal are also active, particularly given the company's Nasdaq listing and Delaware subsidiary structure.

TIP: Candidates targeting Genenta Science should focus on roles that directly support the clinical advancement of Temferon or the operational requirements of a Nasdaq-listed biotech. Clinical operations, GMP manufacturing, regulatory affairs, and quality assurance are consistently in demand at companies at this stage of drug development.

For international candidates considering relocation to Milan, it is worth noting that Genenta Science SpA is based at a Milan address consistent with the city's growing status as a hub for Italian biotech and life sciences. The broader Milan life sciences ecosystem includes partnerships with universities, hospital research centres, and the San Raffaele institute, which creates a supportive environment for scientific careers.

Candidates who want to explore current listings alongside the broader European life sciences job market can browse English-speaking jobs in Europe to identify roles in biotech, pharmaceuticals, and clinical research that align with their skills and career stage.

KEY TAKEAWAY: Genenta Science hires across clinical operations, GMP manufacturing, regulatory affairs, translational science, IT, and corporate finance, with the most strategically important roles centred on advancing Temferon through Phase 1/2 clinical trial and managing the company's dual Italian and U.S. operational structure.

Understanding which function is most relevant to your background will help you craft a more targeted application and connect more effectively with Genenta's hiring team.

How to Apply for Genenta Science Careers: CV, Cover Letter, and Application Strategy

Applying for roles at Genenta Science requires a tailored, scientifically rigorous approach. The company operates in a highly specialised field where generic applications are unlikely to succeed. Candidates need to demonstrate direct relevance to the gene therapy, cell therapy, clinical development, or operational function they are targeting.

For scientific roles, your CV should clearly reference specific technologies such as Lenti Viral Vectors, GMP manufacturing, hematopoietic stem progenitor cell work, or tumor micro-environment research. Vague descriptions of laboratory experience are insufficient. Hiring teams at companies like Genenta Science will look for named assays, platforms, cell types, and regulatory frameworks you have worked within. If you have published research relevant to immuno-gene therapy or viral vector services, list those publications prominently.

Quick answer: To apply successfully for Genenta Science careers in Europe, candidates should tailor their CV to reference specific gene therapy technologies, clinical trial experience, and GMP frameworks directly relevant to the role. Cover letters should connect the candidate's background to Genenta's Temferon programme and the company's position as a clinical-stage biotechnology employer in the European gene therapy sector.

For clinical operations roles, emphasise your experience managing Phase 1/2 clinical trials, working within EMA or ICH GCP frameworks, coordinating with clinical sites in Europe, and managing ATMP-specific protocols. Clinical operations candidates with experience in oncology trials, particularly those involving advanced therapies or cell and gene therapy products, are strongly positioned.

Cover letters for Genenta Science should be concise and specific. Reference Temferon by name. Explain how your background connects to the company's current clinical development stage. Avoid generic language about being passionate about science or wanting to make a difference. Hiring managers at early-stage biotechs respond to candidates who have clearly done their research and can articulate a precise fit with the company's current priorities.

International candidates applying from outside Italy should be prepared to address relocation willingness, language capabilities, and visa status directly in their application. For non-EU candidates, this is particularly important because Italy requires a work permit for non-EU nationals, and the company will need to assess whether sponsorship is feasible for a given role. More on visa considerations is covered in a later section of this guide.

Candidates can use Faruse career guides to prepare their CV and cover letter for European biotech applications, including guidance on how to present scientific credentials, clinical trial experience, and regulatory expertise in formats that work for European employers.

For IT and corporate roles, focus on your experience with biotech-specific systems, clinical data platforms, and the operational requirements of a Nasdaq-listed company. Sr IT Business Partner candidates should reference specific enterprise systems, data security frameworks, and experience supporting regulated environments such as GxP or 21 CFR Part 11 compliant systems if applicable.

KEY TAKEAWAY: Successful applications to Genenta Science require precise scientific and operational language, clear references to the gene therapy and clinical development context, and a direct connection between your background and the company's current Phase 1/2 development priorities.

Preparing a strong application is only one part of the process, and understanding the salary landscape and visa requirements will help you assess whether a Genenta role is the right fit at this stage of your career.

Salary Benchmarking for Biotech Roles in Milan and the Italian Gene Therapy Sector

Salary expectations for roles at Genenta Science and comparable Italian biotech companies in Milan depend on role category, seniority, specific technical expertise, and the candidate's experience in regulated clinical environments. Italian biotech salaries are generally lower than equivalent roles in Switzerland, Germany, or the Netherlands, but Milan-based positions often come with competitive benefits, research exposure, and access to a world-class scientific ecosystem.

For reference, salary ranges in European biotech at various levels are directional and should be verified using current job postings, recruiter data, and official labour market sources. Candidates are encouraged to use salary benchmarking tools and check live postings to understand current compensation norms before negotiating.

Salary ranges are directional, not guaranteed. Candidates should verify current salary ranges using official sources, recruiter data, and job postings. Italian biotech companies often supplement base salary with stock options or equity participation, which is particularly relevant for Nasdaq-listed companies like Genenta Science where Sponsored ADR holders may participate in long-term incentive programmes.

Compensation information and pay transparency requirements apply differently in Italy compared to Genenta's U.S. operations governed by U.S. federal and local laws. Candidates applying for roles interfacing with the Delaware subsidiary may encounter formal pay transparency disclosures consistent with U.S. requirements. For Italian operations, negotiation norms and compensation structures are shaped by Italian employment contracts, national collective agreements, and sector-specific frameworks.

Candidates can use the Faruse salary benchmark tool to compare compensation expectations across European biotech markets, countries, and role categories before entering salary negotiations.

KEY TAKEAWAY: Salaries for biotech roles at Genenta Science in Milan are competitive within the Italian market and may include equity components, but candidates should benchmark against current postings and recruiter data before accepting an offer, particularly for senior or cross-border roles touching U.S. operations.

With salary expectations clarified, the next critical factor for international candidates is understanding the visa and work permit requirements that apply to working in Italy as a non-EU citizen.

Visa and Work Permit Requirements for International Candidates Targeting Genenta Science in Italy

Italy requires non-EU nationals to obtain a work visa and work permit before beginning employment. For international candidates interested in Genenta Science careers in Europe, understanding Italy's immigration framework is essential before applying or accepting an offer.

EU and EEA citizens have the right to work in Italy without a separate work permit and need only to register their residency after arrival. Non-EU candidates, including those from the United Kingdom post-Brexit, the United States, Canada, Australia, India, and most Asian and African countries, must apply for a work visa under Italy's annual quota system, known as the Decreto Flussi, or through exemptions that apply to specific role categories.

Quick answer: Non-EU candidates applying for Genenta Science careers in Italy need a valid Italian work visa and work permit, which typically requires employer sponsorship and falls within the annual Decreto Flussi quota system. Highly specialised roles in gene therapy, GMP manufacturing, and clinical development may qualify for exemptions or priority processing. Candidates should confirm current requirements with the official Italian immigration authority before applying.

For highly skilled non-EU professionals, the EU Blue Card is an alternative pathway available in Italy. The EU Blue Card is designed for workers in high-demand specialist fields and requires a job offer with a salary above a defined threshold, which varies by year and role. Biotech and life sciences roles in gene therapy and clinical operations are generally well-aligned with Blue Card criteria given the specialist skills required.

Employers like Genenta Science, as a Nasdaq-listed company with a formal HR function and U.S. operations experience, are likely to be more familiar with international hiring requirements than many smaller Italian employers. However, sponsorship availability depends on role urgency, headcount planning, and the specific immigration pathway required. Candidates should raise visa requirements early in the interview process rather than waiting until an offer stage.

Italy's broader life sciences ecosystem benefits from specific policy support, including Free Zones and SEZs in certain southern Italian regions that offer incentives for research and development activities. These frameworks can interact with employment terms for candidates working on qualifying research programmes. The Italian government has also indicated interest in aligning industrial policy with biotechnology development as part of its Strategic Sectors framework, which may improve visa processing for specialist roles over time.

Candidates can explore Faruse visa intelligence to research work permit options, EU Blue Card criteria, and country-specific immigration pathways relevant to Italy and other European markets where gene therapy careers are available.

Requirements can vary by nationality, role, employer, and current immigration rules. Candidates should confirm current requirements with the official Italian immigration authority before applying.

KEY TAKEAWAY: Non-EU candidates targeting Genenta Science careers need Italian work permits, typically through the Decreto Flussi quota system or the EU Blue Card for high-skill roles, and should address visa requirements with the employer early in the hiring process to avoid delays.

Beyond visa logistics, understanding the broader economic and policy context shaping Italian biotech is important for candidates who want to assess long-term career prospects in this sector.

The European Gene Therapy Sector, Italian Biotech, and the Policy Context Shaping Genenta Science Careers

The European gene therapy sector is one of the fastest-growing areas of the life sciences industry, with multiple companies advancing cell and gene therapy programmes from preclinical stages through to European Phase I/II trials and beyond. Italy has positioned itself as a serious participant in this sector, with the San Raffaele Telethon Institute in Milan serving as one of Europe's leading centres for research into Lenti Viral Vectors, hematopoietic stem cell gene therapy, and immuno-oncology.

Genenta Science is a direct product of this Italian research ecosystem. Its connection to Professor Luigi Naldini and the San Raffaele institute reflects a broader Italian national security and industrial policy goal to build globally competitive biotech companies on the basis of domestic scientific excellence. The Italian Chamber of Deputies and government institutions have increasingly recognised biotechnology as a Strategic Sector, with biosecurity and advanced therapy manufacturing forming part of the country's economic security agenda.

At the European level, EU economic security policy has identified advanced biotherapeutics, including cell and gene therapy, as areas of strategic importance. This policy direction, reflected in the European Commission's industrial policy statements and the FT Economic Security Watch's coverage of European biosecurity, creates a supportive environment for companies like Genenta Science that are developing domestically important technologies.

The Italian government's interest in italian national security and strategic sectors has also influenced how it approaches industrial consolidation in life sciences. The concept of an industrial aggregator or industrial consolidator in Italian biotech refers to entities that bring together smaller research companies, academic spin-offs, and manufacturing capabilities under a coordinated commercial structure. Genenta Science's growth trajectory and Nasdaq listing reflect this consolidation tendency, as does the emergence of entities like Saentra Forge in the Italian innovation ecosystem.

Defence and aerospace may seem distant from gene therapy, but they are relevant because the Italian industrial policy framework treats all high-technology sectors including difesa and aerospace components as interconnected parts of a national industrial strategy. EU economic security discussions that encompass cybersecurity, defence, and biosecurity increasingly recognise biotech as a dual-use sector with implications for national competitiveness. This policy context supports sustained public and private investment in Italian biotech, which benefits long-term career prospects for professionals joining companies like Genenta Science.

Internationally, comparisons such as the Kuka-Midea acquisition have informed how European policymakers think about protecting strategic biotechnology assets from foreign acquisition, reinforcing Italy's interest in building domestic biotech champions that remain under European ownership and governance. Investigation into foreign direct investment in sensitive sectors including biotech has become more systematic across the EU, and this affects how companies like Genenta manage their ownership structure and Delaware subsidiary governance.

KEY TAKEAWAY: The European gene therapy sector and Italian biotech are strongly supported by both scientific excellence and evolving EU and Italian industrial policy, creating a structurally positive environment for long-term career development at companies like Genenta Science that sit at the intersection of science, policy, and international capital markets.

Alongside the policy context, the investment landscape around Genenta Science directly affects hiring pace, programme expansion, and career growth potential for professionals joining the company.

Genenta Science on Nasdaq: Investment Context, Market Cap, and What It Means for Careers

Genenta Science's Nasdaq listing under a Sponsored ADR structure means the company is subject to U.S. securities regulations, public reporting requirements, and investor scrutiny through platforms including TipRanks, which provides analyst rating data, biotech stocks coverage, and Smart Investor Picks recommendations for listed companies. Understanding the investment context around Genenta helps candidates assess hiring stability, growth trajectory, and the likelihood of programme expansion.

For a clinical-stage biotechnology company, market cap fluctuates significantly based on clinical trial results, regulatory milestones, and broader biotech sector sentiment. Candidates considering Genenta Science careers should monitor the company's financial position, including its cash runway, which is the primary driver of hiring activity at early-stage biotechs. Companies with limited cash runway may slow hiring between funding rounds, while successful clinical milestones typically trigger capital raises that fund programme expansion and new headcount.

Genenta's use of initial public offerings and subsequent capital markets activity reflects a standard strategy among European biotechs seeking to access U.S. investor capital for advanced therapy programmes that require significant investment. Venture capital firms, hedge funds, and institutional investors that hold Genenta shares or ADRs have a direct interest in the company's clinical development progress and management team stability, which creates accountability at the leadership level that ultimately shapes the working culture for all employees.

Quick answer: Genenta Science is a Nasdaq-listed biotech with a Sponsored ADR structure, and its market cap, analyst ratings from platforms like TipRanks, and access to venture capital and institutional investment directly affect its hiring pace and programme funding. Candidates should track clinical trial milestones and capital raise announcements as indicators of near-term hiring activity.

The mergers and acquisitions context in European biotech is also relevant. As Genenta progresses its clinical pipeline, larger pharmaceutical companies may show interest in partnership or acquisition. Genentech, the U.S.-based Roche subsidiary, is sometimes cited in the context of advanced immuno-oncology research as a comparator or potential partner model, though no specific formal relationship with Genenta has been announced beyond what is publicly disclosed. Candidates should always verify current company status through official communications.

Disclaimer: Investment-related commentary in this guide is for general context only and does not constitute financial or investment advice. Candidates should refer to official Genenta Science investor relations materials and consult qualified financial advisers for investment decisions.

KEY TAKEAWAY: Genenta Science's Nasdaq listing and access to international capital markets affect hiring timelines, programme expansion, and employee equity participation, and candidates should track clinical and financial milestones when assessing the timing and stability of career opportunities at the company.

Beyond corporate finance, understanding the practical science of how Genenta's platform extends into the knowledge ecosystem around university partnerships and venture capital relations provides important context for candidates interested in the research culture at the company.

University Partnerships, Knowledge Hubs, and the Venture Capital Question in Biotech Research

The relationship between university research and venture capital in biotechnology is complex, and Genenta Science sits directly at the intersection of these two worlds. The company's scientific origins in Professor Luigi Naldini's work at the San Raffaele Telethon Institute exemplify the academic-to-industry transition that is common across the European gene therapy sector. Understanding this relationship matters for candidates who are considering a move from academic research into commercial biotech.

The question of whether university researchers and venture capital investors can genuinely see eye-to-eye is a recurring topic across the biotech knowledge hub community. Academic researchers prioritise publication, peer review, and scientific rigour, while venture capital investors and Nasdaq-listed company boards focus on clinical milestones, commercialisation timelines, and return on investment. Genenta Science navigates this tension by maintaining strong scientific credibility through its advisory relationships with the San Raffaele institute while also meeting the reporting and milestone expectations of its Nasdaq investor base.

For candidates moving from university or academic research environments into Genenta Science or similar Italian biotech companies, this tension is practically important. You will need to adapt from an environment that values publication cycles and exploratory research to one that values clinical validation, regulatory documentation, and development timelines. The translational scientist role is typically the bridge position that most effectively spans these two cultures.

The broader European biotech knowledge hub ecosystem includes events and forums such as the Praexidia Foundation and venues like Sala Refettorio and Via del Seminario in Milan, which serve as gathering points for Italian research, industry, and policy communities. These environments are where scientific ideas, investment discussions, and career opportunities intersect, and they are worth engaging with for candidates building their network in the Italian life sciences ecosystem.

The field is also moving rapidly into adjacent areas. Proximity degraders, xenotransplantation, and synthetic biology are among the topics generating significant research interest in the European gene therapy and advanced therapy community. Candidates with expertise in these areas may find that their skills are increasingly relevant to Genenta's pipeline as the company expands beyond its initial Glioblastoma multiforme indication.

Similarly, 3D bioprinting and additive manufacturing are entering the biotech conversation as tools for tissue engineering and model development. While Genenta's current platform is focused on cell-based gene therapy rather than 3D bioprinting, the integration of these technologies with advanced therapy manufacturing is a trend that candidates in the field should monitor.

KEY TAKEAWAY: Genenta Science operates at the intersection of academic gene therapy research and commercial biotech development, and candidates making the transition from university research should prepare to adapt their skills and communication style to a clinical milestone-driven, investor-accountable working environment.

For candidates ready to move from research to application, the next step is understanding how to use platforms and resources effectively to find and apply for roles at Genenta Science and comparable European biotech employers.

How Faruse Helps International Candidates Find Biotech and Gene Therapy Jobs in Europe

Finding specialist roles in European biotech requires more than browsing a single job board. International candidates targeting companies like Genenta Science need to combine targeted job search with company research, salary benchmarking, recruiter discovery, and application preparation in order to compete effectively. Faruse brings these elements together in a single European career platform designed specifically for English-speaking professionals.

Faruse allows candidates to search thousands of English-speaking jobs in Europe filtered by country, city, industry, role, and work type. For biotech candidates targeting Italy, the Netherlands, Germany, or other European life sciences markets, this means being able to identify relevant roles quickly and compare them across markets without manually checking multiple sources.

The platform includes company search functionality through Faruse's company search, which allows candidates to research employers, understand their hiring history, and identify companies operating in the gene therapy, cell therapy, and clinical development spaces. This is particularly useful for candidates who want to build a target employer list beyond Genenta Science to include comparable Italian biotech, German pharma, or Dutch life sciences companies.

Recruiter discovery through Faruse's recruiter database helps candidates identify specialist life sciences and biotech recruiters operating in Italy, Germany, the Netherlands, and other European markets. Direct recruiter outreach is often more effective than applying cold to job listings, particularly for senior or specialist roles in small companies where formal job postings may not reflect all available opportunities.

For candidates preparing applications, Faruse offers CV optimisation and cover letter support tools designed to help international professionals present their credentials in formats that work for European employers. This is particularly important for candidates moving from academic research into commercial biotech, where CV structure and language conventions differ significantly from academic CVs or resumes.

Faruse also provides visa intelligence and salary benchmarking resources that help candidates assess whether a target country, role, and employer match their immigration situation and financial expectations before investing time in a full application process. For non-EU candidates targeting Italy specifically, these tools help clarify whether a work permit pathway exists and what salary threshold to expect.

KEY TAKEAWAY: Faruse supports international candidates searching for biotech and gene therapy careers in Europe by combining job discovery, company research, recruiter access, CV support, salary benchmarking, and visa intelligence in a single platform focused on English-speaking opportunities across European markets.

Understanding the common mistakes that international candidates make when targeting European biotech roles will help you avoid the most frequent barriers to success in your search.

Common Myths About Finding Biotech and Gene Therapy Careers in Europe Debunked

MYTH: You need to be fluent in Italian to work at an Italian biotech company like Genenta Science.

FACT: Genenta Science operates internationally, maintains a Nasdaq listing, and has U.S. operations that require English as the primary business language. While Italian is useful for daily life in Milan and for interfacing with local clinical sites, many operational, scientific, and corporate roles at Italian biotech companies function primarily in English. The company's scientific publications, investor communications, and regulatory submissions are conducted in English, and international candidates with strong English and specialist biotech expertise regularly succeed in similar environments.

MYTH: European biotech companies never sponsor visas for non-EU candidates in specialist roles.

FACT: Sponsorship availability depends on role urgency, candidate scarcity, and company size, but clinical-stage biotechs like Genenta Science do hire non-EU candidates for highly specialist roles in GMP manufacturing, viral vector science, regulatory affairs, and clinical operations when qualified EU candidates are not available. The EU Blue Card pathway in Italy exists specifically to facilitate specialist non-EU hires. Candidates should raise visa requirements early and be prepared to work through the process collaboratively with the employer's HR team.

MYTH: Sending the same CV to every biotech job listing will produce results.

FACT: Clinical-stage biotechs like Genenta Science have small, expert hiring teams that review applications closely. A CV that references generic laboratory experience will be rejected in favour of one that specifically addresses Lenti Viral Vectors, GMP manufacturing, hematopoietic stem cell work, or the relevant clinical trial framework. Tailoring your CV to each role and employer is not optional in specialist biotech hiring; it is the baseline expectation.

MYTH: Job boards alone are sufficient to find and land a role at a European biotech like Genenta Science.

FACT: Many roles at early-stage biotechs are filled through network referrals, recruiter relationships, and direct outreach before they are ever publicly listed. Candidates who only monitor job boards miss a significant portion of the available opportunity. Combining job board search with recruiter outreach, LinkedIn engagement, conference networking, and direct company research produces significantly better results, particularly for senior and specialist roles.

MYTH: Italian biotech salaries are too low to justify relocating from a higher-wage market.

FACT: While Italian biotech salaries are generally lower than equivalent roles in Switzerland or Germany, Milan-based positions at Nasdaq-listed companies like Genenta Science often include equity participation, research exposure to world-class scientific programmes, and access to the San Raffaele ecosystem that has long-term career value exceeding the base salary. The total compensation and career trajectory value of joining a clinical-stage biotech at the right stage often exceeds the short-term salary premium available at a larger, later-stage company.

KEY TAKEAWAY: The most common barriers to biotech careers in Europe are language assumptions, visa misconceptions, generic applications, and over-reliance on job boards, all of which can be overcome with targeted preparation, specialist positioning, and a multi-channel job search strategy.

Step-by-Step Job Search Workflow for International Candidates Targeting Genenta Science and European Biotech

A structured approach to searching for biotech careers in Europe will significantly increase your chances of success compared to a passive application strategy. The following workflow is designed for international candidates targeting specialist roles at companies like Genenta Science or comparable European gene therapy and cell therapy employers.

KEY TAKEAWAY: A structured, research-led job search workflow that combines company research, salary benchmarking, visa planning, tailored applications, recruiter outreach, and interview preparation produces significantly better results than passive job board browsing for competitive biotech roles in Europe.

With the workflow in place, reviewing common questions about Genenta Science careers and European biotech job search will help you prepare for every stage of the process.

Frequently Asked Questions

What is Genenta Science and what does the company do?

Genenta Science SpA is a clinical-stage biotechnology company headquartered in Milan, Italy, listed on the Nasdaq through a Sponsored ADR. The company develops immuno-gene therapy treatments for cancer using a platform based on hematopoietic stem progenitor cells engineered with Lenti Viral Vectors to deliver Interferon-alpha into the tumor micro-environment through tumor-infiltrating monocytes. Its lead programme, Temferon, is in Phase 1/2 clinical trial targeting Glioblastoma multiforme. Genenta Science was founded on research by Professor Luigi Naldini and maintains scientific ties to the San Raffaele Telethon Institute in Milan.

What types of careers are available at Genenta Science in Europe?

Genenta Science hires across clinical operations, GMP manufacturing, regulatory affairs, translational science, bioinformatics, quality assurance, IT business partnering, finance, and investor relations. The most strategically central roles support the advancement of Temferon through Phase 1/2 clinical trial and the management of the company's dual Italian and U.S. operational structure. Corporate roles including Clinical Operations Lead and Sr IT Business Partner have been publicly associated with the company. Candidates with specialist backgrounds in cell and gene therapy, viral vector science, and clinical-stage biotech operations are particularly relevant.

How do I apply for a job at Genenta Science?

Candidates should apply through Genenta Science's official career pages or through verified job listings on specialist platforms. Successful applications must be tailored to the specific role and should reference Genenta's scientific platform, including Temferon, Lenti Viral Vectors, and the Phase 1/2 clinical development context. Cover letters should demonstrate knowledge of the company's pipeline and clearly connect the candidate's background to Genenta's current development priorities. Generic applications are unlikely to succeed at a company with a small, expert hiring team. International candidates should also address visa status and relocation readiness directly in their application materials.

What skills and experience do Genenta Science careers in Europe require?

Requirements vary by role. Scientific roles require direct expertise in gene therapy, Lenti Viral Vectors, GMP manufacturing, hematopoietic stem cell biology, tumor immunology, or viral vector services. Clinical operations roles require experience managing Phase 1/2 oncology trials under ICH GCP and EMA frameworks, with specific knowledge of advanced therapy medicinal product protocols being highly valued. Regulatory roles require ATMP experience and familiarity with EMA submission processes. Corporate roles require biotech financial management, Nasdaq reporting awareness, or GxP-compliant IT systems experience depending on the function.

Does Genenta Science sponsor visas for international candidates?

Genenta Science has U.S. operations experience and an international hiring profile that suggests familiarity with cross-border employment processes. However, visa sponsorship availability depends on the specific role, candidate scarcity, and current immigration frameworks in Italy. Non-EU candidates require Italian work permits, typically obtained through the Decreto Flussi quota system or the EU Blue Card pathway for highly skilled workers. Candidates should raise visa requirements with Genenta's HR team early in the hiring process. Requirements can vary by nationality, role, employer, and current immigration rules, and candidates should confirm current requirements with official Italian immigration authorities before applying.

What is the salary range for biotech roles at Genenta Science in Milan?

Salary ranges at Genenta Science and comparable Italian biotech companies in Milan are directional and depend on role, seniority, and specific expertise. Clinical operations leads typically earn in the range of 60,000 to 90,000 EUR annually in Milan, while GMP manufacturing specialists may earn 45,000 to 70,000 EUR depending on viral vector or cell therapy experience. Regulatory affairs managers and IT business partners typically fall in the 55,000 to 80,000 EUR range. Equity participation through stock options or ADR programmes may supplement base salary. Candidates should verify current salary ranges using recruiter data and live job postings before negotiating.

Is English sufficient to work at Genenta Science in Italy?

Many roles at Genenta Science function primarily in English given the company's Nasdaq listing, U.S. operations, international scientific publications, and cross-border investor relations. Scientific, clinical, regulatory, and corporate roles at the international interface are conducted in English. Italian language skills are useful for daily life in Milan and for managing relationships with local clinical sites or government bodies, but they are not typically a prerequisite for specialist scientific or corporate roles. Candidates should review each specific role description for language requirements.

What is Temferon and why does it matter for Genenta Science careers?

Temferon is Genenta Science's lead immuno-gene therapy programme designed to treat solid tumors including Glioblastoma multiforme. It uses engineered bone marrow stem cells carrying a Lenti Viral Vector encoding Interferon-alpha, which is delivered into the tumor micro-environment through tumor-infiltrating monocytes. Temferon has progressed to Phase 1/2 clinical trials, making it the primary driver of Genenta's clinical operations, manufacturing, regulatory, and translational science hiring needs. Understanding Temferon's mechanism and development stage is essential for candidates applying for any role that directly supports the company's pipeline.

Are there remote or part-time job options available at Genenta Science?

Most hands-on scientific, GMP manufacturing, and clinical operations roles at Genenta Science require on-site presence in Milan or at clinical trial sites. Some corporate, regulatory, IT, and finance roles may offer hybrid working arrangements, particularly for positions with significant U.S. interface given time zone requirements. Remote options are more common in functions like investor relations, medical writing, or data management. Candidates interested in remote or flexible arrangements should clarify expectations during the interview process. For broader remote job options in European biotech, candidates can explore remote jobs in Europe on Faruse.

How does Faruse help international candidates find biotech jobs in Europe?

Faruse helps international candidates search English-speaking jobs across Europe by country, city, industry, and role, including biotech and life sciences positions in Italy, Germany, the Netherlands, and other major European markets. The platform supports candidates with CV optimisation, cover letter tools, salary benchmarking, recruiter discovery, company research, and visa intelligence. For candidates targeting the European gene therapy sector, Faruse provides a structured way to combine job discovery with the application preparation and market intelligence needed to compete for specialist roles at companies like Genenta Science.

What is the European gene therapy sector and which countries are most active?

The European gene therapy sector encompasses companies, academic institutions, and clinical programmes developing cell and gene therapy products for genetic diseases, blood cancer, solid tumors, and other conditions. Italy, Germany, the Netherlands, France, and the United Kingdom are among the most active countries, each with established research centres, regulatory frameworks, and clinical development ecosystems. Italy is particularly notable due to the San Raffaele Telethon Institute's contributions to Lenti Viral Vector technology and hematopoietic stem cell gene therapy, both of which underpin Genenta Science's platform. The European Medicines Agency provides the regulatory framework for Advanced Therapy Medicinal Products across EU member states.

What is the difference between CAR-T cell therapies and Genenta Science's approach?

CAR T-cell immunotherapies involve engineering a patient's T-cells to express chimeric antigen receptors that target cancer cells, and they have shown strong results in liquid tumors such as blood cancer. Genenta Science's approach with Temferon differs in that it uses hematopoietic stem progenitor cells rather than T-cells, and it delivers Interferon-alpha into the solid tumor micro-environment via tumor-infiltrating monocytes rather than directly engaging tumour surface antigens. This distinction is important because solid tumors have historically been less responsive to CAR-T approaches due to immune tolerance and the immunosuppressive tumor micro-environment, which is exactly what Temferon is designed to overcome.

How does Genenta Science's Nasdaq listing affect its hiring and culture?

Genenta Science's Nasdaq listing means the company is subject to public reporting requirements, investor scrutiny, and market cap fluctuations that directly influence hiring pace and programme expansion. Successful clinical milestones typically trigger capital raises that fund new headcount and programme activities. The company's Delaware subsidiary structure and U.S. operations add compliance requirements around pay transparency and compensation information consistent with applicable U.S. federal and local laws. The Nasdaq environment also creates a performance-focused, milestone-driven culture that differs from academic research environments, which candidates should prepare for when transitioning from university roles.

Are internships or graduate programmes available in European biotech?

Internship and graduate programme opportunities in European biotech are available through both company programmes and academic-industry partnerships. Early-career candidates interested in gene therapy, cell therapy, and immuno-oncology should target both company internship programmes and research internships through affiliated university institutes such as the San Raffaele Telethon Institute. For broader internship opportunities across Europe, candidates can explore English-speaking internships in Europe and graduate programmes in Europe through Faruse.

What common mistakes should international candidates avoid when applying for European biotech jobs?

The most common mistakes include submitting a generic CV without tailoring it to the specific gene therapy technology or clinical stage relevant to the role, failing to research the company's pipeline in depth before an interview, waiting until an offer stage to address visa requirements with the employer, relying solely on job boards without engaging specialist recruiters or building a professional network in the sector, and underestimating the importance of regulatory knowledge for roles at companies navigating the ATMP framework under EMA guidance. Preparing a targeted, evidence-rich application that demonstrates genuine knowledge of Genenta's platform significantly improves the likelihood of progressing through the hiring process.

Conclusion

Genenta Science careers in Europe offer a rare combination of scientific depth, clinical significance, and international market exposure for professionals in gene therapy, immuno-oncology, GMP manufacturing, regulatory affairs, and biotech operations. As a Nasdaq-listed Italian biotech advancing Temferon through Phase 1/2 clinical trials for Glioblastoma multiforme, Genenta Science sits at the frontier of the European gene therapy sector and offers genuine long-term career potential for candidates who can demonstrate specialist relevance and commitment to the company's mission. International candidates should prepare thoroughly, tailor every application, address visa requirements early, and benchmark salary expectations before negotiating. To discover current English-speaking biotech and life sciences roles across Europe alongside company research, recruiter access, and application support tools, start exploring English-speaking jobs in Europe on Faruse and build a focused application plan for your target role, company, and European market.